Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Female Reproductive System Neoplasm: early-phase trial registry
11 of 19 indexed Malignant Female Reproductive System Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 11 currently recruiting · #902 of 28,707 conditions by registered trial count
Malignant Female Reproductive System Neoplasm: 19 US clinical trials tracked, 11 recruiting.
Malignant Female Reproductive System Neoplasm is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition malignant-female-reproductive-system-neoplasm
OPEN 11 | RECR 58% | LATE 2 | EARLY 7 | RANK #902 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Burnout (58% recruiting · 19 trials)
Malignant Female Reproductive System Neoplasm lists 11 open slots (58% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Female Reproductive System Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Female Reproductive System Neoplasm is recruiting above its size-band peers.
11 of 19 indexed trials (57.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Female Reproductive System Neoplasm research.
M.D. Anderson Cancer Center accounts for 4 of 19 trials (21.1%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Malignant Female Reproductive System Neoplasm enrolment sits around 140 participants.
Median target enrolment is 140 among the 19 trials that report a genuine target (sentinel values excluded). 9 of those (47.4%) plan for fewer than 100 participants.
-
Malignant Female Reproductive System Neoplasm research is mostly interventional.
16 interventional and 3 observational studies make up this index (84.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
NCT05564377
Cancer Genetic Testing in Ethnic Populations
Mayo Clinic
NCT04475640
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
University of California, San Francisco
NCT06089083
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
Wake Forest University Health Sciences
NCT07215624
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
Wake Forest University Health Sciences
NCT05625360
Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery
Mayo Clinic
NCT06525740
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT06126276
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
Emory University
NCT06709534
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer
Mayo Clinic
NCT06855524
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
NCT07407647
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
NCT03968406
Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery
City of Hope Medical Center
NCT04596384
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
NCT01552434
Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
M.D. Anderson Cancer Center
NCT04266886
Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer
M.D. Anderson Cancer Center
NCT00791635
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study
City of Hope Medical Center
NCT05786456
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
NCT04456140
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
City of Hope Medical Center
NCT03776253
EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery
Wake Forest University Health Sciences
NCT03379376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Female Reproductive System Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Female Reproductive System Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Female Reproductive System Neoplasm page
19 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Malignant Female Reproductive System Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Malignant Female Reproductive System Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Female Reproductive System Neoplasm condition card totals 19 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.